Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bispecific antibody shows promise for Hard-to-Treat lymphoma in Real-World study

NCT ID NCT07695896

Disease control Sponsor: Yanyan Liu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study looks at how well a drug called glofitamab (a bispecific antibody) works for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are observing about 200 adults in China who are already receiving this drug as part of their regular care. The goal is to see how many patients have their tumors shrink or disappear, and to track any side effects, providing real-world evidence on the drug's effectiveness and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
glofitamab (a bispecific antibody)
What this could lead to
If successful, this study could show that bispecific antibodies like glofitamab are effective and safe for treating relapsed or refractory B-cell non-Hodgkin lymphoma in everyday clinical practice, potentially offering a new treatment option.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. The treatment may not work for everyone, and side effects are possible. The study is also limited to a Chinese population, which may not generalize globally.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with relapsed or refractory B-cell non-Hodgkin lymphoma who receive a CD20xCD3 bispecific antibody-containing regimen (e.g., glofitamab) in routine clinical practice at participating hospitals in China.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>= 18 years at the start of treatment * Histologically confirmed B-cell non-Hodgkin lymphoma * Relapsed or refractory disease after at least one prior line of systemic therapy * Planned to receive a CD20xCD3 bispecific antibody-containing regimen after study initiation * Signed informed consent for the investigational treatment Exclusion Criteria: * Currently participating in, or planning to participate in, any interventional clinical trial * Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsed or refractory B cell non-Hodgkin lymphoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma Recurrence relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsed or refractory B cell non-Hodgkin lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.